Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
P/S ratio for Ocuphire Pharma, Inc. (OCUP)
P/S ratio as of 2023: 3.41
According to Ocuphire Pharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.41. At the end of 2022 the company had a P/S ratio of 1.77.
P/S ratio history for Ocuphire Pharma, Inc. from 2005 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 3.41 |
| 2022 | 1.77 |
| 2021 | 94.06 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 0.00 |
| 2009 | 0.00 |
| 2008 | 0.00 |
| 2007 | 0.00 |
| 2006 | 0.00 |
| 2005 | 211415.35 |